Company news
ImmuPharma plc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
ImmuPharma appoints worldwide key opinion leaders
July 8, 2013
?50M Financing Facility - Darwin Strategic
May 21, 2013
Posting of Annual Report and AGM Notice
April 22, 2013
ImmuPharma Commences Trading on Stuttgart Exchange
February 28, 2013
Director/PDMR Shareholding - Replacement
January 28, 2013
Lupuzor Presentation
November 15, 2012
Notification of Major Interest in Shares
October 3, 2012
First Cancer Patients in New Trial Begin Dosing
September 26, 2012
Rodman and Renshaw Conference
September 7, 2012
Voted Best Medical Research & Development Company
July 11, 2012
New Corporate Website
July 9, 2012
Annual General Meeting: 2012
May 23, 2012
Appoints Head of Investor Relations
February 29, 2012
Director's Dealings
January 24, 2012
LupuzorT granted approval to start phase III
November 3, 2011
ImmuPharma regains Lupuzor rights
October 21, 2011
Interim results announcement
September 30, 2011
Result of Annual General Meeting
May 19, 2011
IPP-204106 paper published
May 5, 2011
Annual Report and Accounts & Notice of AGM
April 26, 2011
Notification of Preliminary Results
March 30, 2011
Update on progress of Phase I/IIa Clinical Trial
February 21, 2011
Update on Phase IIa Clinical
October 19, 2010
Notification of major interes
October 11, 2010
Notification of Interim Resul
September 28, 2010
Presentation at the Internati
June 28, 2010
Replacement of Development re
June 23, 2010
Annual Report and Accounts
June 10, 2010
Initiation Of Phase I/IIA Stu
May 19, 2010
Best Drug Development Company
April 8, 2010
ING take 4% stake in ImmuPhar
January 5, 2010
R&D Symposium at the CNRS in
December 3, 2009
Positive Final Lupuzor Trial
November 19, 2009
'Best Technology 2009' Award
October 19, 2009
8th Annual Bio Investor Forum
September 21, 2009
JMP Healthcare Focus Conferen
September 17, 2009
Directors' Dealings
July 23, 2009
Piper Jaffray Europe Conferen
June 17, 2009
Share Options
February 4, 2009
Cephalon license exercise
February 2, 2009
Successful trial results
January 30, 2009
further instalment of grant
December 22, 2008
Option Agreement with Cephalo
November 25, 2008
Grant Award
November 12, 2008
Patents Granted
October 21, 2008
Additional Listing and Total
October 17, 2008
AGM Result
August 5, 2008
Second Placing
July 10, 2008
Toxicology study
July 2, 2008
Pre-clinical Data
May 20, 2008
Calls
Decks
- Investor Presentation (April 2020)
Investor deck · 15 slides · April 2020